Complement System

Complement System製品

• All (17)
• Complement System阻害剤 (11)
• Complement System拮抗剤(2)
• Complement System作動薬(2)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Signal Transduct Target Ther, 2025, 10(1):230 Signal Transduct Target Ther, 2025, 10(1):394 Gut, 2025, gutjnl-2025-336105
S2286	Cyclosporin A	Cyclosporin A, a non-polar cyclic oligopeptide, is an immunosuppressive agent that binds to cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay. Cyclosporin A is generally given following transplant surgery to prevent rejection and has been used to test its toxic effect on a perfused 3D proximal tubule model.Cyclosporin A (NSC 290193) can be used to induce animal models of Chronic Rejection of Liver Transplantation.	Signal Transduct Target Ther, 2025, 10(1):81 Signal Transduct Target Ther, 2025, 10(1):167 Adv Sci (Weinh), 2025, 12(36):e06150
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Acta Pharm Sin B, 2024, 14(8):3528-3542 STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Proc Natl Acad Sci U S A, 2025, 122(12):e2426107122 J Tradit Chin Med, 2025, 45(4):739-746 Cancer Cell, 2024, 42(9):1507-1527.e11
S8522	Compstatin	Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.	Nat Commun, 2025, 16(1):2493 Proc Natl Acad Sci U S A, 2025, 122(20):e2412447122 CNS Neurosci Ther, 2025, 31(1):e70216
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	CNS Neurosci Ther, 2025, 31(1):e70216 Invest Ophthalmol Vis Sci, 2025, 66(5):2 Cell Death Dis, 2023, 14(4):285
S3612	Rosmarinic acid	Rosmarinic acid (RA, Rosemary acid) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.	Theranostics, 2025, 15(6):2523-2543 World J Clin Oncol, 2025, 16(5):105341 Free Radic Biol Med, 2021, S0891-5849(21)00198-2
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
S3240	Phaseoloidin	Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. Phaseoloidin has anti-complement effects.
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.
P1269New	Pegcetacoplan acetate	Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis).
S0803	Danicopan	Danicopan is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
E0119	LNP023 (Iptacopan) Hydrochloride	Iptacopan (LNP023) Hydrochloride is a first-in-class, orally administered, potent and highly selective factor B inhibitor with an IC50 of 12 nM and a Kd value of 7.9 nM. Iptacopan exhibits excellent selectivity over other proteases affording IC50s of >30 μM across a panel of 41 human proteases.
S9138	Picfeltarraenin IA	Picfeltarraenin IA is an AChE inhibitior, and an potential PI3K and EGFR inhibitor. It also acts as an inhibitor on both the classical and alternative pathways of the complement system.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Signal Transduct Target Ther, 2025, 10(1):230 Signal Transduct Target Ther, 2025, 10(1):394 Gut, 2025, gutjnl-2025-336105
S2286	Cyclosporin A	Cyclosporin A, a non-polar cyclic oligopeptide, is an immunosuppressive agent that binds to cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay. Cyclosporin A is generally given following transplant surgery to prevent rejection and has been used to test its toxic effect on a perfused 3D proximal tubule model.Cyclosporin A (NSC 290193) can be used to induce animal models of Chronic Rejection of Liver Transplantation.	Signal Transduct Target Ther, 2025, 10(1):81 Signal Transduct Target Ther, 2025, 10(1):167 Adv Sci (Weinh), 2025, 12(36):e06150
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Acta Pharm Sin B, 2024, 14(8):3528-3542 STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Proc Natl Acad Sci U S A, 2025, 122(12):e2426107122 J Tradit Chin Med, 2025, 45(4):739-746 Cancer Cell, 2024, 42(9):1507-1527.e11
S8522	Compstatin	Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.	Nat Commun, 2025, 16(1):2493 Proc Natl Acad Sci U S A, 2025, 122(20):e2412447122 CNS Neurosci Ther, 2025, 31(1):e70216
S3612	Rosmarinic acid	Rosmarinic acid (RA, Rosemary acid) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.	Theranostics, 2025, 15(6):2523-2543 World J Clin Oncol, 2025, 16(5):105341 Free Radic Biol Med, 2021, S0891-5849(21)00198-2
S3240	Phaseoloidin	Phaseoloidin, a homogentisic acid glucoside from Nicotiana attenuata trichomes, contributes to the plant's resistance against lepidopteran herbivores. Phaseoloidin has anti-complement effects.
P1269New	Pegcetacoplan acetate	Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis).
S0803	Danicopan	Danicopan is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
E0119	LNP023 (Iptacopan) Hydrochloride	Iptacopan (LNP023) Hydrochloride is a first-in-class, orally administered, potent and highly selective factor B inhibitor with an IC50 of 12 nM and a Kd value of 7.9 nM. Iptacopan exhibits excellent selectivity over other proteases affording IC50s of >30 μM across a panel of 41 human proteases.
S9138	Picfeltarraenin IA	Picfeltarraenin IA is an AChE inhibitior, and an potential PI3K and EGFR inhibitor. It also acts as an inhibitor on both the classical and alternative pathways of the complement system.
S8931	SB290157 trifluoroacetate	SB290157 trifluoroacetate (SB 290157 TFA) is a potent, competitive and selective antagonist of C3a receptor (C3aR) with IC50 of 200 nM for RBL-C3aR.	CNS Neurosci Ther, 2025, 31(1):e70216 Invest Ophthalmol Vis Sci, 2025, 66(5):2 Cell Death Dis, 2023, 14(4):285
E1048	JR14a	JR14a, a selective and potent human Complement C3a receptor antagonist, which is assessed by inhibition of intracellular calcium release (IC50=10 nM) induced in human monocyte-derived macrophages by C3a, inhibition of β-hexosaminidase secretion (IC50=8 nM) from human LAD2 mast cells degranulated by C3a, and selectivity for human C3aR over C5aR.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
P1269New	Pegcetacoplan acetate	Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis).